Advertisement

Boost Gamma Knife Radiosurgery During Multimodality Management of Medulloblastoma/PNET Tumors

  • Thomas Flannery
  • Douglas Kondziolka
  • L. Dade Lunsford
Chapter
Part of the Pediatric Cancer book series (PECA, volume 3)

Abstract

Medulloblastoma/primitive neuroectodermal tumors (PNETs) are the most common malignant tumors of the central nervous system in children accounting for at least 20% of all childhood brain tumors (Kleihues and Cavenee (eds) Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer, Lyon, 2000). Multimodal treatment, including maximal feasible resection, fractionated neuraxis radiation therapy, and systemic chemotherapy is considered the standard initial strategy against these tumors. In spite of this, local and metastatic recurrences occur in 30–40% of patients, and such recurrences portend a poor prognosis for survival (Kleihues and Cavenee (eds) Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer, Lyon, 2000).

Stereotactic radiosurgery has been proposed as a potentially effective adjunctive therapy in the management of recurrent or residual medulloblastoma (as reported by Patrice, Tarbell, Goumnerova, Shrieve, Black, and Loeffler, Pediatr Neurosurg 22:197–203, 2005). At the University of Pittsburgh, Gamma Knife stereotactic radiosurgery (GKRS) was used in the treatment of 7 pediatric and 12 adult patients who underwent a total of 36 procedures for residual, locally recurrent and metastatic medulloblastoma/PNET tumors. GKRS was administered to pediatric patients who failed initial multimodal treatment. The procedure was well tolerated and none of the patients experienced adverse radiation effects. Local tumor control was more likely in patients with smaller irradiated tumor volumes. Ultima-tely, delayed local progression, distant relapse, or leptomeningeal seeding led to the death of all pediatric patients in our series. Further efforts to develop more effective strategies are needed for this patient population.

Keywords

Gamma Knife Stereotactic Radiosurgery Local Disease Control Central Nervous System Malignancy Atypical Teratoid Rhabdoid Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements/Disclosures

Drs. Lunsford, Kondziolka, and Niranjan are consultants with AB Elekta. Dr. Lunsford is a stockholder in AB Elekta. The work described in this report was funded by a grant to Dr. Flannery from the Irish Institute of Clinical Neuroscience, the Ethicon Foundation Fund R.C.S. (Edinburgh), Friends of the Royal Travel Fund, Northern Ireland Medical & Dental Training Agency, and the Congress of Neurological Surgeons. The authors report no other potential conflicts of interest.

References

  1. Abe M, Tokumaru S, Tabuchi K, Kida Y, Takagi M, Imamura J (2006) Stereotactic radiation therapy with chemotherapy in the management of recurrent medulloblastomas. Pediatr Neurosurg 42:81–88PubMedCrossRefGoogle Scholar
  2. Albright AL, Wishoff JH, Zelter PM, Boyett JM, Rorke LB, Stanley P (1996) Effects of medulloblastoma resections on outcome in children: a report from the Children’s Cancer Group. Neurosurgery 38:265–271PubMedCrossRefGoogle Scholar
  3. Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, Hudson MM, Donaldson SS, King AA, Stovall M, Krull KR, Robison LL, Packer RJ (2009) Long-term outcomes among adult survivors of childhood central nervous system malignancies in the childhood cancer survivor study. J Natl Cancer Inst 101(13):946–958PubMedCrossRefGoogle Scholar
  4. Behdad A, Perry A (2010) Central nervous system pri­mitive neuroectodermal tumors: a clinicopathologic and genetic study of 33 cases. Brain Pathol 20(2):441–450PubMedCrossRefGoogle Scholar
  5. Bowers DC, Gargan L, Weprin BE, Mulne AF, Elterman RD, Munoz L, Giller CA, Winick NJ (2007) Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastoma. J Neurosurg 107(1 Suppl):5–10PubMedGoogle Scholar
  6. Butturini AM, Jacob M, Aguajo J, Vander-Walde NA, Villablanca J, Jubran R, Erdreich-Epstein A, Marachelian A, Dhall G, Finlay JL (2009) High-dose chemotherapy and autologous hematopoietic progenitor cell rescue in children with recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors: the impact of prior radiotherapy on outcome. Cancer 115(13):2956–2963PubMedCrossRefGoogle Scholar
  7. Curran EK, Le GM, Sainani KL, Propp JM, Fisher PG (2009) Do children and adults differ in survival from medulloblastoma? A study from the SEER registry. J Neurooncol 95(1):81–85PubMedCrossRefGoogle Scholar
  8. Flannery T, Kano H, Martin JJ, Niranjan A, Flickinger JC, Lunsford LD, Kondziolka D (2009) Boost radiosurgery as a strategy after failure of initial management of pediatric primitive neuroectodermal tumors. J Neurosurg Pediatr 3:205–210PubMedCrossRefGoogle Scholar
  9. Frange P, Alapetite C, Gaboriaud G, Bours D, Zucker JM, Zerah M, Brisse H, Chevignard M, Mosseri V, Bouffet E, Doz F (2009) From childhood to adulthood: long-term outcome of medulloblastoma patients. The Institut Curie experience (1980–2000). J Neurooncol 95(2):271–279PubMedCrossRefGoogle Scholar
  10. Gaijjar A,Hernan R, Kocak M, Fuller C,Lee Y, McKinnon PJ, Wallace D, Lau C, Chintagumpala M, Ashley DM, Kellie SJ, Kun L, Gilbertson RJ (2004) Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22(6):984–993Google Scholar
  11. Germanwala AV, Mai JC, Tomycz ND, Niranjan A, Flickinger JC, Kondziolka D, Lunsford LD (2008) Boost Gamma Knife surgery during multimodality management of adult medulloblastoma. J Neurosurg 108:204–209PubMedCrossRefGoogle Scholar
  12. Haberler C, Laggner U, Slavic I, Czech T, Ambros IM, Ambros PF, Budka H, Hainfellner JA (2006) Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am J Surg Pathol 30:1462–1468PubMedCrossRefGoogle Scholar
  13. Jenkin D (1996) Long-term survival of children with brain tumors. Oncology (Williston Park) 10(5):715–719Google Scholar
  14. Johnston DL, Keene D, Bartels U, Carret AS, Crooks B, Eisenstat DD, Fryer C, Lafay-Cousin L, Larouche V, Moghrabi A, Wilson B, Zelcer S, Silva M, Brossard J, Bouffet E (2009) Medulloblastoma in children under the age of three years: a retrospective Canadian review. J Neurooncol 94(1):51–56PubMedCrossRefGoogle Scholar
  15. Kleihues P, Cavenee WK (eds) (2000) Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer, LyonGoogle Scholar
  16. Kortmann RD, Kühl J, Timmermann B, Mittler U, Urban C, Budach V, Richter E, Willich N, Flentje M, Berthold F, Slavic I, Wolff J, Meisner C, Wiestler O, Sorensen N, Warmuth-Metz M, Bamberg M (2000) Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT ’91. Int J Radiat Oncol Biol Phys 46(2):269–279PubMedCrossRefGoogle Scholar
  17. Laughton SJ, Merchant TE, Sklar CA, Kun LE, Fouladi M, Broniscer A, Morris EB, Sanders RP, Krasin MJ, Shelso J, Xiong Z, Wallace D, Gajjar A (2008) Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J Clin Oncol 26(7):1112–1118PubMedCrossRefGoogle Scholar
  18. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system. IARC Press, LyonGoogle Scholar
  19. Patrice SJ, Tarbell NJ, Goumnerova LC, Shrieve DC, Black PM, Loeffler JS (1995) Results of radiosurgery in the management of recurrent and residual medulloblastoma. Pediatr Neurosurg 22:197–203PubMedCrossRefGoogle Scholar
  20. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415(6870):436–442PubMedCrossRefGoogle Scholar
  21. Ranger A, McDonald W, Bauman GS, Del Maestro R (2009) Effects of surgical excision and radiation on medulloblastoma cell invasiveness. Can J Neurol Sci 36(5):631–637PubMedGoogle Scholar
  22. Ridola V, Grill J, Doz F, Gentet JC, Frappaz D, Raquin MA, Habrand JL, Sainte-Rose C, Valteau-Couanet D, Kalifa C (2007) High-dose chemotherapy with auto­logous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer 110(1):156–163PubMedCrossRefGoogle Scholar
  23. Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM (2001) Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children’s Cancer Group study. J Clin Oncol 19(15):3470–3476PubMedGoogle Scholar
  24. Rosenfeld A, Kletzel M, Duerst R, Jacobsohn D, Haut P, Weinstein J, Rademaker A, Schaefer C, Evans L, Fouts M, Goldman S (2010) A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors. J Neurooncol 97(2):247–255PubMedCrossRefGoogle Scholar
  25. Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A (2008) Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res 14:971–976PubMedCentralPubMedCrossRefGoogle Scholar
  26. Russo C, Pellarin M, Tingby O, Bollen AW, Lamborn KR, Mohapatra G, Collins VP, Feuerstein BG (1999) Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer 86:331–339PubMedCrossRefGoogle Scholar
  27. Saunders DE, Hayward RD, Phipps KP, Chong WK, Wade AM (2003) Surveillance neuroimaging of intracranial medulloblastoma in children: how effective, how often, and for how long? J Neurosurg 99(2):280–286PubMedCrossRefGoogle Scholar
  28. Souweidane MM, Morgenstern PF, Christos PJ, Edgar MA, Khakoo Y, Rutka JT, Dunkel IJ (2009) Intraoperative arachnoid and cerebrospinal fluid sampling in children with posterior fossa brain tumors. Neurosurgery 65(1):72–78PubMedCrossRefGoogle Scholar
  29. Stavrou T, Bromley CM, Nicholson HS, Byrne J, Packer RJ, Goldstein AM, Reaman GH (2001) Prognostic factors and secondary malignancies in childhood medulloblastoma. J Pediatr Hematol Oncol 23(7):431–436PubMedCrossRefGoogle Scholar
  30. Taylor RE, Bailey CC, Robinson KJ, Weston CL, Ellison DW, Ironside J, Lucraft H, Gilbertson R, Tait DM, Walker DA, Pizer BL, Lashford LS (2004) Impact of radio­therapy parameters on outcome in the International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 study of preradiotherapy chemotherapy for M0-M1 medulloblastoma. Int J Radiat Oncol Biol Phys 58(4):1184–1193PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Thomas Flannery
    • 1
    • 2
  • Douglas Kondziolka
    • 1
  • L. Dade Lunsford
    • 1
  1. 1.Departments of Neurological Surgery and Radiation OncologyUniversity of Pittsburgh Medical CenterPittsburghUSA
  2. 2.Department of Neurosurgery, Royal Hospitals Trust, Belfast, and Leeds Gamma Knife CenterSt. James’s Institute of OncologyLeedsUK

Personalised recommendations